In the present study, we examined the difference in efficacy of rapamycin and paclitaxel on in vitro and in vivo models with or without TTC17 knockdown, and plan to investigate the influence of targeting mTOR and microtubules on the metastasis of TTC17-downregulated breast cancer in a follow-up study to clarify its linkage with the molecular network regulation of drug responsiveness. The gene discussed is MTOR; the disease is breast carcinoma.